V5med Inc.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
1. Pulmonary Image Computer-Aided Interpretation Software: The "V5med Inc." Pulmonary Image Computer-Aided Interpretation Software (Model: V5-MED-LU01) is Taiwan's first artificial intelligence (AI) computer-aided detection (CADe) software featuring high sensitivity and high specificity that has been officially introduced into pulmonary nodule AI clinics.
2. Smart Medical Platform: The V5 Smart Medical Platform can receive scan images from various AI modules and automatically analyze them for multiple clinical findings, operating in real-time and fully integrating with the physician's workflow.
2. Smart Medical Platform: The V5 Smart Medical Platform can receive scan images from various AI modules and automatically analyze them for multiple clinical findings, operating in real-time and fully integrating with the physician's workflow.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
94272481
Status
Active
Number of Employees
0
Total Paid-in
Capital
110,000,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
V5med Inc. is a smart medical startup invested in and established by Brite Technology, focusing on the research, development, and clinical application of artificial intelligence (AI) medical image recognition technology. Its parent company, Brite Technology, is a leading optical defect inspection manufacturer in the semiconductor industry. Having accumulated over a decade of core capabilities in fields such as high-speed image processing, deep learning, and computer vision, it has successfully served the world's top 15 wafer foundries and packaging and testing plants, laying a solid technical foundation for V5med Inc.
Continuing its parent company's technical expertise in high-precision image interpretation, V5med Inc. integrates AI algorithms, clinical knowledge, and cross-platform system integration capabilities to build a lung AI-assisted diagnostic platform centered on low-dose computed tomography (LDCT). The platform provides all-in-one image analysis functions for pulmonary nodules, emphysema, pulmonary fibrosis, coronary artery calcification (CAC), and more, assisting physicians in improving early diagnosis accuracy and reducing the burden of interpretation.
V5med Inc. obtained TFDA medical device clearance at the end of 2022 and officially secured US FDA 510(k) clearance in March 2025, becoming the first lung AI diagnostic software manufacturer in Taiwan to receive US certification. Its products have expanded to Taiwan, Japan, Vietnam, Thailand, Indonesia, and other regions, and the company has launched clinical and commercial collaborations with top medical institutions and distributors in multiple countries. V5med Inc. is committed to making AI-assisted diagnostic technology a core driving force of precision medicine and becoming a leading smart medical brand in Asia.
Continuing its parent company's technical expertise in high-precision image interpretation, V5med Inc. integrates AI algorithms, clinical knowledge, and cross-platform system integration capabilities to build a lung AI-assisted diagnostic platform centered on low-dose computed tomography (LDCT). The platform provides all-in-one image analysis functions for pulmonary nodules, emphysema, pulmonary fibrosis, coronary artery calcification (CAC), and more, assisting physicians in improving early diagnosis accuracy and reducing the burden of interpretation.
V5med Inc. obtained TFDA medical device clearance at the end of 2022 and officially secured US FDA 510(k) clearance in March 2025, becoming the first lung AI diagnostic software manufacturer in Taiwan to receive US certification. Its products have expanded to Taiwan, Japan, Vietnam, Thailand, Indonesia, and other regions, and the company has launched clinical and commercial collaborations with top medical institutions and distributors in multiple countries. V5med Inc. is committed to making AI-assisted diagnostic technology a core driving force of precision medicine and becoming a leading smart medical brand in Asia.
The content above was translated by Ai
